Trimeris raises $43.4 million

TRMS, which is in Phase III testing of its T-20 HIV fusion inhibitor to treat HIV infection/AIDS, raised $43.4 million in a private placement of 1.4 million shares at $31. TRMS was down $0.83 to $36.8...